GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Neurophet 380550.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

5,240

+0.58%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Neurophet

Its shares trade on KOSDAQ under the ticker 380550.KQ. It has been listed since 25 July 2025. In the fiscal year to 31 December 2025, it reported revenue of ₩2.62bn and a net loss of ₩22.39bn. At that date it held total assets of ₩26.88bn and shareholders' equity of ₩19.45bn.

Neurophet Inc is a KR-based company operating in Health Care Technology industry. The company is headquartered in Seoul, Seoul. The company went IPO on 2025-07-25. Neurophet Inc is a Korea-based company principally engaged in the research, development and sales of brain imaging analysis software. The firm is mainly engaged in the development and sale of positron emission tomography (PET) image quantitative analysis software ‘Neurophet SCALE PET’, neurodegenerative brain disease diagnosis support software ‘Neurophet AQUA’ and other products. In addition, the Company is engaged in the development and sale of therapeutic medical devices. The firm is also engaged in the provision of medical artificial intelligence (AI) solutions.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Technology
Listed since
25 Jul 2025
Employees
135

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company operates in Health Care Technology industry with headquarters in Seoul.
  • Employs 135 full-time employees and has an IPO date of 2025-07-25.
  • Develops and sells brain imaging analysis software including Neurophet SCALE PET and Neurophet AQUA.

Weaknesses

  • Company is based in Korea with limited international presence.
  • IPO is scheduled for 2025-07-25, indicating a relatively new market entry.
  • Relies on specific products like Neurophet SCALE PET and Neurophet AQUA for revenue.

Opportunities

  • Growing demand for medical AI solutions in the health care sector.
  • Potential expansion into international markets for brain imaging software.
  • Increasing focus on neurodegenerative disease diagnosis tools.

Threats

  • Competition from established health care technology firms.
  • Regulatory challenges in medical device and AI software development.
  • Dependence on specific product lines for revenue generation.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.